Travere Therapeutics, Inc.

Good morning and welcome to Travere Therapeutics' second quarter 2026 financial results conference call. Today's call is being recorded. At this time, I would like to turn the conference over to Nivi Nehra, Vice President, Corporate Communications and Investor Relations. Please go ahead, Nivi.

Thank you, operator. Good afternoon and welcome to Travere Therapeutics' second quarter 2026 financial results and corporate update call. Thank you all for joining. Today's call will be led by Dr. Eric Dube, our President and Chief Executive Officer. Eric will be joined in the prepared remarks by Peter Heerma, our Chief Commercial Officer, Dr. Jula Inrig, our Head of R&D and Chief Medical Officer, and Chris Cline, our Chief Financial Officer. Dr. Bill Rote, our Chief Research Officer, will join us for the Q&A. Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by the statement. Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factors section in our Forms 10-Q and 10-K filed with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made, August 4th, 2026. Interviewers specifically disclaims any obligations to update such statements to reflect future information, events or circumstances. With that, let me now turn the call over to Eric. Eric?

Thank you, Nivi. Good afternoon and thank you for joining us today. The second quarter was exceptional. Our performance demonstrates the strength of the company we are building and the disciplined execution of our teams. Travere has now entered a new chapter, one that we expect will deliver near and long-term growth driven by clear momentum across four key pillars. Continued growth for Filspari in IJ nephropathy, the successful launch of Filspari in FSGS, the advancement of PEG to Batenase in its pivotal phase three study, and the addition of Sivobrutinib to our rare kidney disease pipeline. At the center of this strategy is Filspari, which we believe is becoming an increasingly important rare kidney disease medicine. This was the first quarter with Filspari commercially available across both IJ Nephropathy and FSGS, and we are very pleased with the performance. Our teams delivered growth in IgA nephropathy demand compared to last quarter despite additional market entrants and achieved successful early adoption in the first months of the FSGS launch that exceeded our high expectations. Peter will provide more detail on the launch shortly, but we are encouraged by the early performance. As we build on Phil Sparey's commercial momentum, We continue to advance our intellectual property strategy. During the quarter, the USPTO issued a Notice of Allowance for a US patent application directed to certain methods of using sparsentin in Hygiene Apropathy. Upon issuance, the patent is expected to provide US patent coverage for those methods. We also continue to pursue additional patent coverage for sparsentin, including through a pending U.S. application directed to certain methods of using sparsentin in FSGS. Beyond PhilSparry, we are building a robust pipeline of potential disease-modifying, best-in-class medicines that is strategically aligned with our rare kidney disease expertise and positioned to drive long-term growth. Pegdibatinase remains a very important program for Trevir and for the HCU community. It has the potential to become the first and only disease-modifying therapy for classical homocysteineuria, a rare metabolic disease affecting 7,000 to 10,000 patients and their families in the U.S. today. With pivotal data expected next year, PEG-2-Batinase is positioned to become the next medicine we deliver from our pipeline to address a significant unmet need within the rare disease community. We are also very pleased to recently close our exclusive licensing agreement with Everest Medicines for Siborabrutinib, adding a differentiated upstream immune modulating approach to our rare kidney disease portfolio with potential application across multiple immune mediated kidney diseases. While it is still early, we see Siborabrutinib as a meaningful long term growth opportunity in addition to Filspari and Pegdibatinase. With continued momentum across our business, we are entering the second half of the year from a position of considerable strength. I'd now like to turn the call over to Peter for a commercial update. Peter?